Four sessions ago, ACMEPL traded 11.15 million shares to lead the Dhaka Stock Exchange in volume. Today, it lost more than every other pharma name on the bourse except one. Acme Pesticides Limited closed Sunday at Tk 24.40 — down Tk 1.20 from Thursday’s close of Tk 25.60, a 4.69% single-session decline. From the Jun 3 peak of Tk 26.10, the cumulative drop is 6.51% across three trading days.
That round-trip is not random. It is the third time in five weeks that a DSE pharma speculative name has executed the same pattern: volume spike, price surge, sharp reversal within one to three sessions. And the second name to print the pattern today — Asiatic Laboratories — fell 4.85% in a near-mirror image of ACMEPL’s tape.
The pattern has a structure. The structure has a profile. Both deserve attention before the next iteration.
The Session in Numbers
ACMEPL opened at Tk 25.50 — adjusted to Tk 25.60 against Thursday’s close. Within the session, the stock printed a high of Tk 25.90 and a low of Tk 24.10 before settling at Tk 24.40. The intraday range covers 7.4% of the closing price. There was no recovery off the low; the stock sold off steadily through the afternoon and closed within Tk 0.30 of the day’s bottom.
Volume tells the story underneath. 6,875,887 shares changed hands across 3,899 trades, generating Tk 171.94 million in turnover — roughly 1.1% of the entire DSE’s Tk 15,290.55 million session total. That is heavy distribution. Single-stock turnover above 1% of bourse total, on a declining price, is the textbook signature of supply outpacing demand. The buyers who chased ACMEPL above Tk 26 last Wednesday are now the sellers. The next bid is lower.
The Jun 3 session had already flagged the setup. The stock surged 6.10% on 11.15 million shares to lead DSE volume — concentrated participation in a single counter on a day when 243 issues advanced. Concentration without conviction. Today’s tape is the resolution of that concentration.
The Two-Stock Echo
ASIATICLAB fell 4.85% on the same session. Asiatic Laboratories closed at Tk 129.40 against a YCP of Tk 136.00, with an intraday swing from Tk 137.90 to Tk 125.10 — a 9.3% high-to-low range in one trading day. Volume of 1.05 million shares moved Tk 138.55 million in value. Both stocks are classified under Pharmaceuticals & Chemicals. Both were among the heaviest turnover names earlier this month. Both topped today’s pharma loser list with declines inside 0.16 percentage points of each other.
The broader pharma sector was mixed on Sunday: ten advanced, eight declined. ASIAPACINS gained 5.63%. RENATA added 2.50%. BXPHARMA rose 1.12%. This was not a pharma selloff. It was a selloff in two specific pharma names with identical trading signatures — heavy speculative volume, recent price spikes, technical exhaustion.
The May 6 ASIATICLAB crash followed the same blueprint — yesterday’s pharma star became the worst loser within hours. The May 21 pharma split wrote the same script with different actors. Three repetitions in five weeks is no longer coincidence. It is a tradable pattern with a name and a recovery curve — as ASIATICLAB’s eventual 6.54% bounce demonstrated.
The Fundamentals Beneath the Tape
ACMEPL is loss-making. Nine-month EPS for fiscal 2026 sits at negative Tk 0.75. Q1 at negative Tk 0.10. Q2 at negative Tk 0.16. Q3 at negative Tk 0.49 — the loss is accelerating, not narrowing. Trailing P/E of -28.05 is mathematically derivable but economically meaningless: you cannot value a company on negative earnings, and yet 6.88 million shares traded today as though the multiple compression argument mattered.
The 52-week range of Tk 11.00 to Tk 27.80 is the more useful lens. At Tk 24.40, ACMEPL still trades 121.8% above its 52-week low and only 12.2% below its 52-week high. The stock has more than doubled from its low against a backdrop of widening losses. That entire move is multiple expansion on no earnings. Multiple expansion on no earnings is the definition of a speculative bid — and speculative bids unwind on technical signals, not fundamental ones.
The Jun 3 surge was technical. Today’s reversal is technical. The next leg will also be technical.
What to Watch
The next iteration of the pharma whipsaw will arrive in another loss-making mid-cap with a recent volume spike, a price within 15% of its 52-week high, and a sector classification under Pharmaceuticals & Chemicals. The setup is identifiable in real time. The reversal is identifiable in hindsight. ACMEPL’s three-session round-trip from Tk 26.10 to Tk 24.40 just gave you the most recent template — and ASIATICLAB printed the confirming copy on the same tape. Whether ACMEPL finds support near Tk 23 or unwinds toward its 200-day mean depends on whether the next buyer chases the volume signature or waits for earnings that the last four quarters say are not coming.
The pattern repeats because the structure rewards it. Until DSE retail learns to distinguish liquidity surges from re-ratings, the same trade will keep printing — and the same investors will keep funding the round-trip.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. ACME Pesticides Limited is a loss-making company at the time of writing. All trading decisions should be made in consultation with a licensed financial advisor. Past price patterns do not guarantee future outcomes.